Skip to Content
Merck
All Photos(2)

Key Documents

915408

Sigma-Aldrich

NanoFabTx PEGylated nanoparticle formulation screening kit

Synonym(s):

NanoFabTx reagent kit, Nanoparticle synthesis kit, PEGylated nanoformulations

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
NACRES:
NA.23

description

Kit components :
PEGPLGA-50L (912808-500mg)
PEGPLGA-75L (913049-500mg)
PEGPLA-L (913308-500mg)
PEGPCL-H (912549-500mg)
Stabilizer - P (913448-10g)

Materials screening kit, for synthesis of PEGylated polymeric nanoparticles

Quality Level

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PEGylated nanoparticle formulation screening kit contains optimized reagents and protocols for nanoprecipiation and microfluidic-based synthesis of polymer nanoparticles. The kit provides rationally selected PEGylated PLGA, PLA, and PCL polymers, which are widely used in drug delivery systems for controlled drug release of many different types of therapeutic molecules. This reagent kit can be combined with the NanoFabTx Microfluidic - nano device kit (Cat.No. 911593) for microfluidic synthesis of polymer nanoparticles 60 to 100 nm in size.

Application

NanoFabTx PEGylated nanoparticle formulation screening kit is designed for the synthesis of specifically sized, hydrophobic drug encapsulated biodegradable PEGylated polymer nanoparticles. Our specially designed PEGylated polymers result in nanoparticles with a PEG surface coating that reduces protein absorption and prolongs circulation time, leading to slow and sustained release of the encapsulated drug. The NanoFabTx PEGylated nanoparticle formulation screening kit enables nanoparticle optimization by selection of the right polymer to achieve the desired nanoparticle size, drug encapsulation, release kinetics, and stability in systemic circulation. This kit provides reagents and protocols for nanoprecipitation and microfluidics to synthesize 60 nm to 100 nm nanoparticles.

Features and Benefits

  • Provides step-by-step protocols, both for standard extrusion or microfluidic-based synthesis, developed and tested by our formulation scientists
  • Microfluidic formulation development for enhancing drug bioavailability
  • Flexible synthesis tool to create uniform and reproducible nanoparticles
  • Optimized to make nanoparticles from 60-100 nm
  • Includes 4 different PEGylated polymers to identify the optimal material

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

12 - Non Combustible Liquids


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
Robert F Pagels et al.
Journal of controlled release : official journal of the Controlled Release Society, 219, 519-535 (2015-09-12)
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices
Byung Kook Lee et al.
Advanced drug delivery reviews, 107, 176-191 (2016-06-06)
Poly(d,l-lactic acid) (PLA) has been widely used for various biomedical applications for its biodegradable, biocompatible, and nontoxic properties. Various methods, such as emulsion, salting out, and precipitation, have been used to make better PLA micro- and nano-particle formulations. They are

Articles

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service